Similar articles

• [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].

  Hotta N, Sakamoto N. Hotta N, et al. Nihon Rinsho. 1987 Dec;45(12):3010-27. Nihon Rinsho. 1987. PMID: 3128677 Review. Japanese. No abstract available.
• Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.

  Jacobson M, Sharma YR, Cotlier E, Hollander JD. Jacobson M, et al. Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1426-9. Invest Ophthalmol Vis Sci. 1983. PMID: 6413448
• [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].

  Christensen JE, Larsen AB, Gregersen G. Christensen JE, et al. Ugeskr Laeger. 1987 Nov 9;149(46):3111-4. Ugeskr Laeger. 1987. PMID: 3127975 Clinical Trial. Danish. No abstract available.
• Can aldose reductase inhibition ameliorate diabetic neuropathy?

  González ER. González ER. JAMA. 1981 Sep 11;246(11):1169-70. doi: 10.1001/jama.1981.03320110003001. JAMA. 1981. PMID: 6790734 Clinical Trial. No abstract available.
• The pharmacology of aldose reductase inhibitors.

  Kador PF, Robison WG Jr, Kinoshita JH. Kador PF, et al. Annu Rev Pharmacol Toxicol. 1985;25:691-714. doi: 10.1146/annurev.pa.25.040185.003355. Annu Rev Pharmacol Toxicol. 1985. PMID: 3923907 Review. No abstract available.